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Pelvic radiotherapyObjective: Radiation-induced acute intestinal symptoms (RIAISs) are a common complication of radio-
therapy for cervical cancer. The aim of this study was to use 1H nuclear magnetic resonance (1H NMR)
combined with chemometric analysis to develop a metabolic proﬁle of patients with RIAISs.
Methods: Fecal samples were collected from 66 patients with cervical cancer before and after pelvic
radiotherapy. After radiotherapy, RIAISs occurred in eleven patients. We selected another 11 patients
from participants without RIAISs whose age, stage, histological type and treatment methods are matched
with RIAIS patients as the control group. 1H NMR spectroscopy combined with multivariate pattern
recognition analysis was used to generate metabolic proﬁle data, as well as to establish a
RIAIS-speciﬁc metabolic phenotype.
Results: Orthogonal partial least-squares discriminant analysis was used to distinguish samples between
the pre- and post-radiotherapy RIAIS patients and between RIAIS patients and controls. Fecal samples
from RIAIS patients after pelvic radiotherapy were characterized by increased concentrations of
a-ketobutyrate, valine, uracil, tyrosine, trimethylamine N-oxide, phenylalanine, lysine, isoleucine, glu-
tamine, creatinine, creatine, bile acids, aminohippurate, and alanine, accompanied by reduced concentra-
tions of a-glucose, n-butyrate, methylamine, and ethanol relative to samples from RIAIS patients before
pelvic radiotherapy, while in RIAIS patients relative to controls, trimethylamine, n-butyrate, fumarate and
acetate were down-regulated and valine, TMAO, taurine, phenylalanine, lactate, isoleucine and creatinine
were up-regulated.
Conclusions: We obtained the metabolic proﬁle of RIAIS patients from fecal samples using NMR-based
metabonomics. This proﬁle has the potential to be developed into a novel clinical tool for RIAIS diagnosis
or therapeutic monitoring, and could contribute to an improved understanding of the disease mecha-
nism. However, because of the limitations of methods, technique, bacterial contamination of feces and
small sample size, further research and veriﬁcation are needed.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 117 (2015) 294–301
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Radiotherapy is often the deﬁnitive therapy for management of
patients with locally advanced cervical cancer and patients who
are poor candidates for surgery [1]. It is also used as an adjuvant
therapy in patients who have undergone radical hysterectomy
and have one or more pathologic risk factors, such as
positive nodes and/or positive surgical margins [1,2]. However,radiotherapy causes radiation-induced acute intestinal symptoms
(RIAISs) in 50–80% of cervical cancer patients [1,3–5]. RIAISs
include abdominal pain, diarrhea, and tenesmus, which may lead
to dose reduction, treatment interruptions, increased healthcare
costs, and impaired quality of life [6]. Studies on RIAISs have
mainly focused on genomics, proteomics, or cell-based assays
[1,7,8], which do not adequately show the endpoint changes that
occur in the pathological state.
Metabonomics is a new and rapidly developing ﬁeld that
studies the detection, identiﬁcation, and quantiﬁcation of
low-molecular-weight metabolites that are involved in metabo-
lism [9,10]. The concentration and relative ratio of metabolites
Table 1
Clinical and demographic information on all 66 cervical cancer patients, 11 of whom
developed RIAISs.
Characteristics Participants RIAISs Controls
No. of women 66 11 11
Age (years)
Median/mean 53/52.1 54/51.9 55/54.2
Range 30–70 30–67 37–65
FIGO stage
I 10 2 2
II 37 6 7
III 13 2 2
IV 6 1 0
Histological type
Squamous carcinoma 64 11 11
Adenocarcinoma 2 0 0
Therapy
Radical hysterectomy and adjuvant
radiotherapy
34 7 7
Radical radiotherapy 32 4 4
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and proteomic factors. The metabolic proﬁle may provide
important information about the health of an individual.
Metabonomics can be used as a complementary tool, providing
information about the metabolic network that cannot be obtained
directly from the genotype, gene expression proﬁles, or even the
proteome of an individual [10]. In addition, it can be used to iden-
tify early signals/biomarkers of cellular abnormalities that occur
before the appearance of gross phenotypic changes [11].
Metabonomics has been successfully applied to disease diagnosis
[12–14], biomarker screening [15–19], and biological pathway
characterization [9].
Recent technological advances in nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry have further
improved the sensitivity and spectral resolution of metabonomic
studies [20]. NMR spectroscopy is a powerful tool that is widely
applied in metabolite identiﬁcation and quantiﬁcation. The advan-
tages of NMR spectroscopy over other methods are that it allows
for nontargeted metabolic proﬁling and is a nondestructive
method that requires little or no sample preparation [21]. 1H
NMR is especially attractive because protons are present in virtu-
ally all metabolites, and the sensitivity of 1H is the highest among
all NMR-observable nuclei [21]. 1H NMR is routinely used to mon-
itor perturbations in the metabonome by collecting
one-dimensional (1D) spectra of sample extracts, followed by mul-
tivariate data analysis by, for example, principal component anal-
ysis (PCA) or partial least-squares discriminant analysis (PLS-DA)
[22,23].
Exposure to ionizing radiation during pelvic radiotherapy of the
intestines induces mucosal inﬂammation, apoptosis of endothelial
cells of the microvessels and crypt cells, and chemotaxis and
thrombogenesis of damaged vessels [8]. These events lead to the
occurrence of RIAISs, with changes in the stool representing the
earliest and most direct manifestation. Therefore, feces may be
an ideal biomedium for studying RIAISs. In addition, feces are read-
ily available, easily obtained, and less complex than other body ﬂu-
ids or tissues. Ease of collection allows for fecal sampling to
monitor disease and therapeutic response, thereby making the
clinical application more convenient. These advantages led us to
use patient fecal samples to study RIAIS metabonomics. In this
study, we used 1H NMR combined with chemometric analysis to
identify metabolic biomarkers of RIAISs in cervical cancer patients,
and to develop an RIAIS-speciﬁc metabolic phenotype, which will
aid in our understanding of the pathobiology of the disease.Materials and methods
Patients and treatment
The study protocol was approved by the Ethics Committee of
the First Afﬁliated Hospital of Xi’an Jiaotong University. Informed
consent was obtained from each participant before sample collec-
tion. The study was conducted as part of a previously published
trial that focused on biomarker screening for RIAISs by serum pro-
teomic analysis [1]. Sixty-six cervical cancer patients with ade-
quate organ function and performance status were recruited to
participate in this study. All patients had no history of colitis, dia-
betes, or pelvic inﬂammatory disease. A summary of the patients’
characteristics is displayed in Table 1.
The previously published treatment protocol was followed for
this study [1]. Of the 66 recruited patients, 34 patients underwent
radical hysterectomy followed by external-beam radiotherapy
(EBRT) (surgery-based group). Radical hysterectomy included
resection of the uterus along with its attached parametrial soft tis-
sue, a margin of the upper vagina, and pelvic lymphadenectomy.
EBRT was delivered 2–4 weeks later, using a linear accelerator ofthree-dimensional conformal radiation therapy. Computed
tomography-based treatment planning was used for all patients.
The clinical target volume included the common, external, and
internal iliac lymph node regions and the upper 3.0 cm of the
vagina. The superior margin of the external radiation ﬁeld was
located at the abdominal aortic bifurcation. The inferior border
extended to 3.0 cm below the upper extent of the vagina (deﬁned
by the vaginal marker) or to 1.0 cm above the inferior extent of the
obturator foramen. EBRT was delivered to the whole pelvis at
1.8 Gy or 2 Gy per fraction, with ﬁve fractions administered per
week, for a total of 25 fractions and 45–50 Gy. The remaining 32
patients received radical radiotherapy, which consisted of pelvic
EBRT followed by high-dose-rate (HDR)-intracavitary brachyther-
apy (ICBT) (RT-based group). The pelvic radiation ﬁeld was the
same as that employed for the adjuvant radiotherapy, but
extended inferiorly in cases involving vaginal invasion. External
irradiation was delivered to the whole pelvis at 1.8–2 Gy per frac-
tion, with ﬁve fractions administered per week, for a total of 25–28
fractions and 50–50.4 Gy. ICBT was performed by using the
Fletcher-Suit-Delclos set with a microSelectron HDR (Nucletron,
Netherlands). Orthogonal X-rays were administered after each
insertion, to calculate the dwell times for the prescribed Point A
dose. Vaginal packing was used to maximize the distances from
the source to the bladder wall and the rectal wall. The total
planned dose to point A for HDR-ICBT was 24–25 Gy administered
in four or ﬁve fractions. All 32 patients in this group received one
cycle of cisplatin combined with 5-ﬂuorouracil (PF regimen) during
pelvic EBRT as a radiosensitizing agent.
Occurrence of RIAISs was assessed on a daily basis by a single
observer and was graded according to the National Cancer
Institute Common Toxicity Criteria version 2.0. Mild diarrhea,
abdominal pain, and tenesmus appeared in 40% patients when
they received 16–30 Gy EBRT. Diet adjustment and adequate rest
relieved these symptoms for most patients. Patients without
remission who suffered from grade 2 or 3 RIAISs were included
as research candidates. The morning stool specimens of these can-
didates were collected before supportive treatment was adminis-
tered (e.g., antidiarrheal, intestinal protection, and/or oral
anti-infective drugs and, when necessary, intravenous ﬂuids and
nutraceutical treatment). Overall, pelvic EBRT was well tolerated,
with no recorded grade 4 or 5 adverse events. However, RIAISs
occurred in 11 patients (16.7%), of which four and seven patients
experienced grade 2 and 3 proctitis, respectively. The main symp-
toms included abdominal pain, diarrhea, and tenesmus. All cases
296 Metabonomics of Feces of RIAIS patientswere successfully managed by conservative treatment, and the
radiotherapy period was not signiﬁcantly prolonged. Samples were
grouped as follows:
Group A-samples of RIAIS group before radiotherapy.
Group B-samples of the control group before radiotherapy.
Group C-samples of RIAIS group after radiotherapy.
Group D-samples of the control group after radiotherapy.
Sample collection and storage
One fecal sample was collected in the early morning 1–3 days
before radiotherapy for every included patient. Patients fasted
and abstained from alcohol and drugs for 12 h before sample col-
lection. If grade 2 or grade 3 RIAISs occurred during radiotherapy,
another fecal sample was collected before supportive treatment
administration; if not, another fecal sample was collected after
the last EBRT. Stool samples were taken immediately after voiding
and were delivered to the laboratory within 2 h of sample produc-
tion. Multiple 20-mg aliquots were rapidly collected from the same
area below the surface of the stool. These subsamples were imme-
diately frozen at 80 C until required for further analysis.Specimen preparation for 1H NMR analysis
All chemicals and reagents used in this study were purchased
from Sigma–Aldrich (St. Louis, MO, USA), unless otherwise stated.
Fecal samples (stored at 80 C and transported on dry ice) were
thawed at room temperature. Fecal extracts were prepared for
NMR analysis by thoroughly mixing 20 mg of frozen fecal material
with 1 mL of saline phosphate buffer (1.9 mM Na2HPO4, 8.1 mM
NaH2PO4, 150 mM NaCl, and 1 mM sodium 3-trimethylsilyl-tetra
deuteriopropionate) in D2O for 5 min, followed by centrifugation
(12,000g, 10 min, 4 C). Supernatants were removed and ﬁltered
through 0.2-lm membrane ﬁlters. Finally, 550 ll of each ﬁltrate
was transferred to an NMR tube (5 mm outer diameter) for
analysis.1H NMR analysis
1H NMR spectra for all fecal extract samples were collected on a
Varian Unity INOVA 600 NMR spectrometer (Varian, Palo Alto, CA)
with a proton Larmor frequency of 599.92 MHz. Spectra
were acquired using a conventional presaturation pulse
sequence at 25 C with solvent suppression NOESYPR1D
(RD-90-t1-90-tm-90-ACQ, where the relaxation delay was 2.1 s,
mixing time was 0.1 s, and solvent was presaturated during the
relaxation delay and mixing time). For each sample, ID CarrPurc
ellMeiboomGill (CPMG) was performed to ﬁlter out signals
belonging to proteins and other macromolecules, thereby allowing
spectra primarily comprising signals from metabolites and small
molecules to be obtained [24].Multivariate statistics
All free induction decays were multiplied by an exponential
function to a 1.0 Hz line-broadening factor before Fourier transfor-
mation. All 1H NMR spectra were manually phased and
baseline-corrected by using Top Spin (V2.1 BrukerBiospin,
Germany). 1H NMR spectra of fecal samples were referenced to
the internal alanine resonance at d1.48. Then, region d0.6–9.5 of
the spectrum was segmented into a consecutive nonoverlapping
region of d0.01 in width. The region of water resonance (d4.66–
5.20) was excluded to eliminate the baseline effects of an imperfect
water signal. Finally, the remaining bins were integrated and nor-
malized for further analysis.Normalized data were imported into SIMCA-Pt software (V11.0
Umetrics AB, Umea, Sweden). PCA was initially applied to the spec-
tral data to visualize inherent clustering between groups A and B,
groups A and C, groups C and D. After the NMR data were reviewed
by PCA analysis, they were subjected to orthogonal partial
least-squares discriminant analysis (OPLS-DA). A model was built
and utilized to identify marker metabolites that accounted for
the differentiation of all groups [25]. As an extension of PLS-DA,
OPLS-DA features an integrated orthogonal signal correction
(OSC) and can remove variability not relevant to class separation.
Both PLS-DA and OPLS-DA were based on a unit variance scaling
strategy. A 20-fold cross-validation was employed to obtain Q2
and R2 values, which represent the predictive ability of the model
and the explained variance, respectively. To validate the quality of
the PLS-DA model, permutation tests consisting of a randomly per-
muting class membership were carried out with 200 iterations.
Sensitivity, speciﬁcity, and classiﬁcation rate (percentage of sam-
ples correctly classiﬁed) of OPLS-DA models were then depicted
[26].Results
1H NMR CPMG results, showing the average signals from groups
A, B, C and D are depicted in Fig. 1. More than 30 different metabo-
lites were identiﬁed and quantiﬁed according to extant literature
from each dataset of each feces sample based on their chemical
shifts and signal multiplicity. The main differences in peaks
between groups were concentrated in the areas of 0.5–5.5 and
5.5–9.5 ppm (Fig. 1).
To establish a global overview for discrimination between dis-
eases and controls, the following analysis was applied to all NMR
spectral data. First, PCA was used and the score plot (Fig. 2,
R2X = 52.7%, Q2 = 0.122) obtained, with the ﬁrst two principal
components representing 26.8% and 25.8% of the variance. There
was no signiﬁcant difference between groups.
Next, supervised analysis techniques, including PLS-DA and
OPLS-DA, were used. These methods can maximize differences
among groups and aid in the screening of the metabolite markers
responsible for class separation by removing systematic variations
unrelated to pathological state [26]. Based on the PLS-DA models,
group A and group B were discriminated with an R2X of 0.184, an
R2Y of 0.920 and a Q2 of 0.210; group A and group C were discrim-
inated with an R2X of 0.322, an R2Y of 0.836 and a Q2 of 0.096;
group C and group D were discriminated with an R2X of 0.230, an
R2Y of 0.835 and a Q2 of 0.205. The goodness-of-ﬁt (R2 and Q2)
of the original PLS-DA models and cluster of 200 Y-permutated
models were visualized by invalidation plots (Fig. 3). The valida-
tion plots clearly showed that the original PLS-DA models were
valid for groups A and C, as the Q2 regression line had a negative
intercept and all permuted R2 values on the left were lower than
the original point on the right; while for pairwise groups A and B
and groups C and D, there were no particularly signiﬁcant differ-
ence in the metabonomics proﬁles.
The OPLS-DA model was constructed subsequent to PLSDA
analysis using the ﬁrst principal component and the second
orthogonal component. The quality of the models was described
by the cross-validation parameters Q2 and R2X, which represented
the total variation for the X matrix, and the values are tabulated in
Table 1. In OPLS-DA score plots, a signiﬁcant biochemical distinc-
tion between groups A and C was identiﬁed (Fig. 4). In addition,
some degree of separation between groups C and D could also be
visualized (Fig. 4), while distinction between groups A and B isn’t
signiﬁcant.
The metabolic signature associated with each group is derived
from model coefﬁcients obtained from the OPLS-DA model
Fig. 1. 1H NMR spectra (d0.5–5.5 and d5.5–9.5) of fecal samples obtained from groups A, B, C and D. The region of d5.5–9.5 (in the dashed box) was magniﬁed 10 times
compared with corresponding region of d0.5–5.5 for the purpose of clarity. Keys: AA: Acetoacetate; Ace: Acetate; Ade Adenine; AH: aminohippurate; Ala: Alanine; Asp:
Aspartate; BA: Bile acids; Bu: n-Butyrate; Cn: Creatininie; Cr: Creatine; DMA: Dimethylamine; DMG: Dimethylglycine; EA: Ethanolamine; Eth: Ethanol; For: Formate; Fum:
Fumarate; Gln: Glutamine; Glu: Glutamate; Gly: Glycine; GPC: Glycerolphosphocholine; Ile: Isoleucine; Lac: Lactate; Lys: Lysine; M: Malonate; m-I: myo-Inositol; MA:
Methylamine; NT: Nicotinate; Phe: Phenylalanine; Suc: Succinate; Tau: Taurine; Thr: Threonine; TMA: Trimethylamine; TMAO: Trimethylamine N-oxide; Tyr: Tyrosine; U:
Unknown; Ura: Uracil; Val: Valine; a-KB: a-Ketobutyrate; a-Glc: a-Glucose; b-Gal: b-Galactose; b-Glc: b-Glucose.
Fig. 2. PCA scores plot based on 1H NMR spectra of fecal sample from groups A(I),
B(II), C(III) and D(IV).
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Eighteen metabolites were detected at signiﬁcantly different levels
between groups A and C. Our data reveal up-regulation of
a-ketobutyrate, valine, uracil, tyrosine, TMAO, phenylalanine,
lysine, isoleucine, glutamine, creatinine, creatine, bile acids,
aminohippurate and alanine and down-regulation of a-glucose,
n-butyrate, methylamine and ethanol in group C relative to group
A. While in group C relative to group D, trimethylamine, n-buty-
rate, fumarate and acetate were down-regulated and valine,
TMAO, taurine, phenylalanine, lactate, isoleucine and ceatinine
were up-regulated (see Table 2). These data strongly support the
robustness of 1H NMR to identify metabolic changes in the feces
of RIAIS patients prior to radiotherapy from that after radiotherapy
and in the feces of RIAIS patients after radiotherapy from that of
controls after radiotherapy.Discussion
Histological changes induced by RIAISs include edema, hyper-
emia, crypt abscess, ulcers, and necrosis of the intestine.
Occurrence of RIAISs is related to several key factors, including
the volume of exposed bowel, radiotherapy dose, and dose inten-
sity [27]. Many molecular markers, such as tissue factor, von
Willebrand factor, platelet activating factor, and prostacyclin 1
[28–30], may be related to radiation-induced intestinal injury.
Recently, Petersen et al. constructed a condensed anorectal dys-
function score (RT-ARD) by binomial regression analysis and tested
it in separate patient material by receiver operating characteristic
(ROC) analysis with high sensitivity (91%) and speciﬁcity (85%)
[31]. Varela E found that fecal excretion of human DNA and calpro-
tectin increased during pelvic radiotherapy treatment, and may be
a good objective biomarker of intestinal damage in nonrectal
cancer patients [32].
Early accurate judgment of RIAISs can help clinicians to adopt
individualized treatment or take advance measures to avoid or
mitigate the occurrence of RIAISs, guarantee the smooth comple-
tion of radiotherapy, and improve patients’ quality of life.
Biomarker identiﬁcation and validation for radiation injury is a
rapidly expanding ﬁeld. There are currently no sensitive or speciﬁc
biological markers of RIAISs. To date, numerous biomarkers associ-
ated with radiation-induced tissue damage have been identiﬁed
spanning the omics spectrum, including genomics (gene expres-
sion), transcriptomics (DNA damage and repair), proteomics (pro-
tein proﬁles), and metabonomics (metabolites). From a system
biology prospective, metabolites, which generally are referred to
as biological molecules with a molecular mass less than 1000 Da,
represent the end products of cellular processes resulting from
genetic and environmental inﬂuences. The connection between
upstream transcriptomic and proteomic regulation of downstream
metabolomic responses enables metabolomic expression to be cor-
related to phenotypic outcome. Consequently, identiﬁcation of
metabolite biomarkers has received considerable attention from
various disciplines, including those involved in radiation research.
Fig. 3. PLS-DA scores plots (left panel) derived from 1H NMR spectra of fecal samples obtained from group A(I), B(II), C(III) and D(IV) and cross validation (right panel) by
permutation test.
298 Metabonomics of Feces of RIAIS patientsThis is the ﬁrst study to use an NMR-based metabonomics
approach to develop a metabolic proﬁle of RIAIS patients with cer-
vical cancer. We demonstrate distinct differences in the spectra
acquired between the feces of RIAIS patients before and after radio-
therapy, and between RIAISs and controls. In conjunction with sta-
tistical models, we wanted to assess the potential of the technique
as a diagnostic tool for the disease and to identify characteristic
metabolites. More than 30 different metabolites were identiﬁed
and quantiﬁed in each fecal sample based on 1H NMR. Eighteen
metabolites were detected at signiﬁcantly different levels in
RIAIS patients before and after radiotherapy, while eleven metabo-
lites were also detected between RIAIS patients and controls.
Our data revealed increased levels of seven amino acids (i.e.,
tyrosine, alanine, and the essential amino acids valine, isoleucine,
phenylalanine, lysine, and glutamine) in feces from RIAIS patients
after compared to before radiotherapy and three amino acids
(i.e., valine, phenylalanine and isoleucine) in feces from RIAISpatients compared to controls. This ﬁnding suggests that the pro-
tein metabolism changes during active RIAISs. Amino acid metabo-
lism is complex, involving a large number of metabolites [24].
Mucosal injury caused by acute radiation induces mucosal inﬂam-
mation, damages the endothelial cells and microvessels, and trig-
gers apoptosis of intestinal crypt cells, which inﬂuence the
metabolism and absorption of essential amino acids in the intesti-
nal epithelium. Essential amino acids in the intestinal mucosa play
an important role in the regulation of intestinal morphology and
function. For example, glutamine is the main source of energy in
the small intestine, providing a sufﬁcient amount of ATP for active
transport of nutrients and protein turnover of the small intestine.
Damage of the intestinal epithelial and malabsorption of essential
amino acids inﬂuence each other, creating a vicious cycle that fur-
ther exacerbates the RIAIS patient’s symptoms, decreasing the
body content of essential amino acids and resulting in malnutri-
tion. In addition, glutaminase 2 (GLS2) plays an important role in
Fig. 4. OPLS-DA scores plots (left panel) derived from 1H NMR spectra of fecal samples and corresponding coefﬁcient loading plots (right panel) obtained from different
pairwise groups. The color map shows the signiﬁcance of metabolites variations between the two classes. Peaks in the positive direction indicate metabolites that are more
abundant in the groups in the positive direction of ﬁrst principal component. Consequently, metabolites that are more abundant in the groups in the negative direction of ﬁrst
primary component are presented as peaks in the negative direction. Keys of the assignments were shown in Fig. 1. Group A(I), B(II), C(III), D (IV).
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[33] reported that knockdown of GLS2 decreases glutathione and
NADH expression, and sensitizes cervical cancer cells to ionizing
radiation and GLS2 may also regulate radioresistance in cervical
cancer patients. In our study, glutamine levels were upregulated
in the feces of RIAIS patients after radiotherapy compared to
before. We speculated that this result might be due to the lower
expression of glutaminase in the intestinal epithelium, resulting
in increased sensitivity to radiation and intestinal radiation injury.
We observed a downregulation of a-glucose in feces from RIAIS
patients after compared to before radiotherapy. a-Glucose is the
main energy source of intestinal bacteria. Mucosal injury caused
by acute radiation induces mucosal inﬂammation and increases
the number of bacteria, which consume a-glucose in the intestine
and result in downregulation of a-glucose. Creatine, which was
upregulated in feces from RIAIS patients after radiotherapy com-
pared to before and in feces from RIAIS patients compared to con-
trols, can assist in providing energy for muscle and nerve cells and
is considered an effective nutritional ergogenic aid to enhance
exercise performance [34]. Mucosal injury caused by acute radia-
tion causes malabsorption of creatine, which may be one reason
why RIAIS patients tend to experience fatigue.a-Ketobutyrate, a short-chain fatty acid (SCFA), was upregu-
lated in fecal samples from RIAIS patients after radiotherapy, indi-
cating a loss of butyric acid in intestinal epithelial cells. SCFAs are
end-products of the fermentation of dietary ﬁbers by anaerobic
microbiota. They are important in maintaining the morphology
and function of a normal colon and colonic epithelial cells [35].
These effects are achieved through the rapid absorption of SCFAs
in the gut, leading to energy storage and reduced osmolality.
SCFAs also promote the absorption of sodium. Butyric acid loss in
RIAIS patients disrupts sodium reabsorption, leading to loss of
moisture and further aggravating diarrhea. From our ﬁndings, we
infer that the maintenance of SCFAs may have therapeutic poten-
tial in preventing intestinal complications in patients undergoing
pelvic radiotherapy.
Uracil levels were upregulated in RIAIS patients after treatment.
This result may be related to the fact that the patients received
concurrent chemotherapy containing ﬂuorouracil. Bile acid levels
were upregulated in RIAIS patients after radiotherapy, which may
be caused by dyspepsia. Changes of other metabolites such as
TMAO, aminohippurate, methylamine, ethanol, fumarate, acetate,
taurine and lactate have no speciﬁc which requires further exper-
imental veriﬁcation.
Table 2
OPLS-DA coefﬁcients derived from the NMR data of metabolites in fecal samples
obtained from different groups.
Metabolites ra
A–B A–C C–D
a-Ketobutyrate: 1.06(t) – 0.541 –
a-Glucose: 3.71(t), 3.73(m), 3.84(m), 5.24(d) – 0.528 –
Valine: 0.99(d), 1.04(d) – 0.813 0.507
Uracil: 5.81(d), 7.54(d) – 0.544 –
Tyrosine: 6.90(d), 7.20(d) – 0.702 –
Trimethylamine: 2.90(s) – – 0.557
TMAO: 3.29(s) – 0.537 0.501
Taurine: 3.25(t), 3.42(t) – – 0.514
Phenylalanine: 7.32(m), 7.38(t), 7.43(m) – 0.714 0.610
Nicotinate: 8.25(d), 8.61(d), 8.94(d) 0.651 – –
n-Butyrate: 0.90(t), 1.57(m), 2.18(t) – 0.552 0.609
myo-Inositol: 3.54(dd), 3.67(dd), 4.06(t) 0.504 – –
Methylamine: 2.60(s) – 0.520 –
Lysine: 1.73(m), 1.90(m), 3.02(t), 3.76(t) – 0.835 –
Lactate: 1.33(d), 4.13(q) – – 0.543
Isoleucine: 0.96(t), 1.01(d) – 0.830 0.568
Glycerol: 3.62(dd) 0.529 – –
Glutamine: 2.14(m), 2.46(m), 3.78(t) – 0.659 –
Fumarate: 6.53(s) – – 0.652
Ethanol: 1.19(t), 3.63(q) – 0.621 –
Creatinine: 3.06(s), 4.06(s) – 0.628 0.521
Creatine: 3.04(s), 3.93(s) – 0.682 –
Bile acids: 0.72(m) – 0.649 –
Aminohippurate: 6.86(d), 7.74(d) – 0.654 –
Alanine: 1.48(d) – 0.622 –
Acetate: 1.92(s) – – 0.536
a Correlation coefﬁcients, positive and negative signs indicate positive and neg-
ative correlation in the concentrations, respectively. The correlation coefﬁcient of
|r| > 0.500 was used as the cutoff value for the statistical signiﬁcance based on the
discrimination signiﬁcance at the level of p = 0.05. ‘‘’’ means the correlation
coefﬁcient |r| is less than 0.500. Multiplicity: s, singlet; d, doublet; t, triplet; q,
quartet; dd, doublet of doublets; m, multiplet.
300 Metabonomics of Feces of RIAIS patientsIntestinal epithelial tissue is late radiation response organiza-
tion, with a long incubation period and a difﬁculty to predict and
repair. Therefore, ﬁnding an accurate prediction method has great
clinical signiﬁcance. In this study, we used 1H NMR to determine
fecal metabolite proﬁles of RIAIS patients before and after radio-
therapy and that of RIAIS patients compared to controls.
Multivariate analysis showed that the model was able to distin-
guish feces from RIAIS patients before and after radiotherapy with
an accuracy of 100% and to distinguish feces from RIAIS patients
compared to controls with an accuracy of 88.89%. The metabolisms
of amino acids, energy and lipids were signiﬁcantly altered in RIAIS
patient fecal samples after radiotherapy and in RIAIS patients com-
pared to controls.
The identiﬁcation and validation of metabolite biomarkers for
RIAISs has the potential to be both clinically relevant and mecha-
nistically informative. But in this study, it is difﬁcult to identify
patients susceptible to RIAISs before radiotherapy. This may be
because our sample size was too small to screen out meaningful
metabolites and establish speciﬁc model for patients susceptible
to RIAISs compared to non-susceptibility patients before pelvic
radiotherapy. This study revealed that patients susceptible to
RIAISs can be identiﬁed early during pelvic radiotherapy.
Individualized treatment programs could be designed for these
patients. Timely and appropriate protective measures could be
taken, such as more advanced radiation technology to guarantee
radiation dose distribution with high precision. In addition, the
radiation dose could be reduced and the prophylactic administra-
tion of antidiarrheal drugs and other supportive treatment could
be prescribed for patients at risk for RIAISs. These measures could
overcome the discontinuation of pelvic radiotherapy, or at least
alleviate RIAISs. The identiﬁed differentially expressed metabolitesmay represent potential therapeutic targets for RIAISs. However,
whether targeting these metabolites would be beneﬁcial or delete-
rious remains to be established.
Although this experiment shows in principle how feces metabo-
nomics could help to identify patients susceptible to RIAISs as early
as possible and may reduce adverse events in susceptible individ-
uals, there are some limitations. First, feces contain large amounts
of bacteria that can impact metabolite proﬁling. Fecal samples
were collected immediately after defecation and stored at 80 C
to minimize bacterial growth. Another limitation for this study is
the small sample size. Much bigger prospective studies are neces-
sary in the future. At the technical level, although the use of NMR
approaches for radiation injury has yielded important information,
it is an untargeted and discovery-based metabonomic approach. To
understand the effects of RIAISs completely and discovery the
panel of RIAIS biomarkers clearly, further identiﬁcation and valida-
tion are needed.
In conclusion, in this pilot study, we have investigated the
application of 1H NMR spectroscopy-based metabonomics to
detect metabolic changes in the feces of RIAIS patients. Our results
indicate signiﬁcant dysregulation of metabolic pathways in RIAIS
patients. Speciﬁcally, we found that RIAISs were associated with
disrupted amino acid, energy, and lipid metabolisms.Disclosure of potential conﬂicts of interest
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